| abstract |
The invention relates to novel heterocyclyl compounds of the formula (I) (see formula (I)) in which A, X, Y1, Y2, Y3, R3, R4, R5, R6, R7, R8, R9, R10, m, n and p have the meanings defined in the description and in the claims, as well as their physiologically acceptable salts. These compounds are antagonists of the CCR2 receptor, CCR5 receptor and / or CCR3 receptor and can be used as medicaments. |